Investigating the landscape of US orphan product approvals
Abstract Background The Orphan Drug Act was enacted in 1983 to encourage the development of drugs for rare diseases. Previous research has attempted to examine the impact of the Act by assessing either the number of orphan designations that have been granted or the number of new orphan drugs approve...
Main Authors: | Kathleen L. Miller, Michael Lanthier |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-10-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-018-0930-3 |
Similar Items
-
Do investors value the FDA orphan drug designation?
by: Kathleen L. Miller
Published: (2017-06-01) -
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
by: Kathleen L. Miller, et al.
Published: (2021-06-01) -
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
by: Kathleen L. Miller, et al.
Published: (2020-09-01) -
The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study
by: Mohua Chakraborty Choudhury, et al.
Published: (2019-11-01) -
Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01)